However, the rapid decay of neutralizing antibodies against BA.1 and low neutralisation against BA.5 in participants without breakthrough infection suggest that a single booster vaccine dose does not provide sufficient protection against Omicron subvariants. The gene discussed is CFB; the disease is infection.